Edwards Lifesciences Welcomes Updated CMS Policy Expanding TAVR Patient Access

Key Facts

1Edwards Lifesciences issued a statement responding to the updated National Coverage Determination (NCD) for TAVR released by CMS.

In a move reflecting the evolution of healthcare regulatory policies in the United States, Edwards Lifesciences issued a formal statement responding to the updated National Coverage Determination (NCD) released by the Centers for Medicare & Medicaid Services (CMS). The company expressed its approval of the updated policy regarding Transcatheter Aortic Valve Replacement (TAVR), stating it aims to expand access for patients suffering from aortic stenosis, a serious and progressive disease.

Per market data, Edwards Lifesciences (EW) shares closed at $86.18 on September 9, 2026, with the stock trading between a day low of $85.73 and a high of $87.04 during that session. This regulatory clarity from CMS provides support for the company's core product lines, as Edwards emphasized that the update reinforces the multidisciplinary Heart Team approach to patient care.

Looking ahead, investors are monitoring EW's ability to maintain levels above the $85.73 support established at the close of September 9, 2026. With the upcoming economic calendar showing no direct catalysts for the medical device sector, the focus remains on how the expanded coverage will impact the growth trajectory of TAVR procedure volumes in future quarters.